Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy

(2020) Jasmohan S Bajaj et al.   GUT

Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure

(2020) Jonel Trebicka et al.   Nature Reviews Gastroenterology & Hepatology

The IL-17 Family of Cytokines in Health and Disease

(2019) Mandy J. McGeachy et al.   IMMUNITY

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases

(2019) Barbara Ruder et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Mechanisms by Which the Gut Microbiota Influences Cytokine Production and Modulates Host Inflammatory Responses

(2019) Viviani Mendes et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list

(2019) Shayon Salehi et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Identification of Salivary Microbiota and Its Association With Host Inflammatory Mediators in Periodontitis

(2019) Anna Lundmark et al.   Frontiers in Cellular and Infection Microbiology

Rifaximin decreases virulence of Crohn’s disease-associated Escherichia coli and epithelial inflammatory responses

(2018) Belgin Dogan et al.   JOURNAL OF ANTIBIOTICS

Cytokine Tuning of Intestinal Epithelial Function

(2018) Caroline Andrews et al.   Frontiers in Immunology

Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: Is this time to abandon fluoroquinolones for prevention of spontaneous bacterial peritonitis? : A Systematic Review.

(2018) Amr Menshawy et al.   CURRENT DRUG TARGETS

Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial

(2017) Nina Kimer et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis

(2016) Benjamin Lelouvier et al.   HEPATOLOGY

Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis

(2016) Mark J.W. McPhail et al.   JOURNAL OF HEPATOLOGY

The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

(2016) James G. Orr et al.   LIVER INTERNATIONAL

IL-17a and IL-22 Induce Expression of Antimicrobials in Gastrointestinal Epithelial Cells and May Contribute to Epithelial Cell Defense against Helicobacter pylori

(2016) Beverly R. E. A. Dixon et al.   PLoS One

Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease

(2016) Jeffrey M. Flynn et al.   PLoS Pathogens

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy

(2015) Jasmohan S. Bajaj et al.   HEPATOLOGY

The severity of circulating neutrophil dysfunction in patients with cirrhosis is associated with 90-day and 1-year mortality

(2014) N. J. Taylor et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Covert Hepatic Encephalopathy Is Independently Associated With Poor Survival and Increased Risk of Hospitalization

(2014) Kavish R Patidar et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Precision High-Throughput Proton NMR Spectroscopy of Human Urine, Serum, and Plasma for Large-Scale Metabolic Phenotyping

(2014) Anthony C. Dona et al.   ANALYTICAL CHEMISTRY

Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance

(2014) Agustín Albillos et al.   JOURNAL OF HEPATOLOGY

Alterations of the human gut microbiome in liver cirrhosis

(2014) Nan Qin et al.   NATURE

Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats

(2013) Dabo Xu et al.   GASTROENTEROLOGY

Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF)

(2013) Juan Cordoba et al.   JOURNAL OF HEPATOLOGY

Altered profile of human gut microbiome is associated with cirrhosis and its complications

(2013) Jasmohan S. Bajaj et al.   JOURNAL OF HEPATOLOGY

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy

(2013) Jasmohan S. Bajaj et al.   PLoS One

Host sialoglycans and bacterial sialidases: a mucosal perspective

(2012) Amanda L. Lewis et al.   CELLULAR MICROBIOLOGY

Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort

(2012) Emanuel Burri et al.   CLINICA CHIMICA ACTA

Structure, function and diversity of the healthy human microbiome

(2012)   NATURE

Linkage of gut microbiome with cognition in hepatic encephalopathy

(2011) Jasmohan S. Bajaj et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis

(2010) Pablo Bellot et al.   HEPATOLOGY

Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei

(2010) Zhi-Dong Jiang et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Rifaximin Treatment in Hepatic Encephalopathy

(2010) Nathan M. Bass et al.   NEW ENGLAND JOURNAL OF MEDICINE

Delineation of the Innate and Adaptive T-Cell Immune Outcome in the Human Host in Response to Campylobacter jejuni Infection

(2010) Lindsey A. Edwards et al.   PLoS One

Characterization of a Streptococcus sp.-Veillonella sp. Community Micromanipulated from Dental Plaque

(2008) N. I. Chalmers et al.   JOURNAL OF BACTERIOLOGY